Market Overview

Wall Street's M&A Chatter From January 6-8

Share:

The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday January 6 through Sunday January 8, 2017.

Invitae Acquires AltaVoice for $5M in Stock at Closing Plus Up to $10M Based on Milestones

The Deal:

Invitae Corp (NYSE: NVTA) announced it has acquired AltaVoice, a privately owned, patient-centered data company with a global platform for collecting, curating, coordinating, and delivering safeguarded data from patients and clinicians. Invitae purchased all of AltaVoice's stock in exchange for $5 million in Invitae common stock issuable upon closing and up to an additional $10 million in Invitae common stock issuable based on certain future milestones.

Invitae closed Friday at $8.54, down 1.61 percent.

Mast Therapeutics, Savara Sign Merger Agreement; Deal Values Mast at $36.5M

The Deal:

Mast Therapeutics Inc (NYSE: MSTX) and Savara Inc. announced Saturday that the two companies have entered into a definitive merger agreement, valuing Mast at $36.5 million. Current Mast stockholders will collectively own approximately 24 percent, and Savara stockholders will collectively own approximately 76 percent, of the combined company on a pro-forma basis.

Mast Therapeutics closed at $0.10 on Friday, up 3.02 percent.

Merrimack Pharmaceuticals Confirms Plan to Sell ONIVYDE, Generic Version of DOXIL to Ipsen for Up to $1.025B

The Deal:

Merrimack Pharmaceuticals Inc (NASDAQ: MACK) confirmed a Reuters report Sunday that it has entered into a definitive asset purchase and sale agreement with Ipsen (OTC: IPSEY) sell its first commercial product ONIVYDE and its generic version of DOXIL in a transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments. The transaction is expected to be completed in Q1 of 2017.

Merrimack closed at $3.60 on Friday, down 5.26 percent.

Posted-In: M&A News Rumors

 

Related Articles (IPSEY + MACK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Barron's Picks And Pans: Amgen, Barnes & Noble, Expedia And More

Stock Index Futures Steady to Lower in Pre-Market